NCT05498792 - Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2022

Primary Completion Date

March 4, 2026

Study Completion Date

September 2, 2026

Conditions

Locally Advanced or Metastatic Melanoma

Interventions

DRUG

CBL0137

Patient will be enrolled at 3 dose levels of CBL 0137, dose level -1 (320 mg/m²), dose level 1 (400 mg/m²), dose level 2 (540 mg/m²)

DRUG

Ipilimumab

Patient will be on Ipilimumab (1 mg/kg)

DRUG

Nivolumab

Patient will be on Nivolumab (3 mg/kg)

Trial Locations (1)

RECRUITING

Fox Chase Cancer Center, Philadelphia